Clinical Trials

The clinical evaluation of 2-ethylbutyric acid currently features a clinical trial sponsored by Pfizer investigating its therapeutic potential for pneumonia. This completed Phase 1 study evaluated the pharmacokinetics, safety, and tolerability of oral and intravenous formulations. Overall, clinical development remains in the preliminary stage, focusing on early-stage safety profiles and drug disposition for respiratory infection applications.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00759564 Completed
Pneumonia
Pfizer
2008-11 Phase 1

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the 2-Ethylbutyric Acid product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As a branched short-chain fatty acid derivative, 2-ethylbutyric acid interacts with lipid membranes and cellular metabolic enzymes, blocking downstream biochemical cascades and suppressing host inflammatory signaling. This cellular action reduces localized tissue damage and mediator release, demonstrating potential clinical relevance in modulating inflammatory pathology during pneumonia.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.